Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc. (NYSE:CRM) announced that Novartis (NYSE:NVS) selected the company’s Agentforce Life Sciences for Customer Engagement to connect the experiences of patients and healthcare professionals.
Novartis has already invested in the company through Agentforce Health, 360 for Health & Life Sciences, MuleSoft for Life Sciences and Agentforce Marketing. It now plans to unify the participation of marketing, sales, patient services, medical affairs, market access and other teams. Under the agreement, the company will deploy Agentforce 360 for life sciences globally over the next five years.
That said, Wall Street is also bullish on Salesforce, Inc. (NYSE:CRM). On December 17, BTIG’s Allan Verkhovski initiated the stock with a Buy rating and a $335 price target. Previously on December 16, Gregg Moskowitz of Mizuho Securities also reiterated a Buy rating on the stock with a $340 price target.
BTIG analyst Verkhovski likes the restructuring of the company’s core platform. He added that Salesforce management has expressed confidence that the net value of annual new orders will accelerate and exceed the overall value of annual orders over the next year. The firm projects that the company will return to double-digit subscription revenue growth in the fiscal fourth quarter of 2027.
Salesforce, Inc. (NYSE:CRM) provides customer relationship management technology, connecting businesses and customers.
While we recognize the potential of CRM as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.